Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Chemotherapy in Treating Patients With Retinoblastoma

Phase 2

Completed

Conditions: Retinoblastoma

First Posted Date: 2004-07-29

Last Posted Date: 2013-06-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00002675

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-07-29

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002588

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2012-07-02

Lead Sponsor: Northwestern University

Registration Number: NCT00004169

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: paclitaxel
Drug: topotecan hydrochloride
Radiation: radiation therapy

First Posted Date: 2004-07-22

Last Posted Date: 2016-07-20

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 75

Registration Number: NCT00003812

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

and more 45 locations

Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-07-19

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00002557

Locations: 🇿🇦
University of Cape Town School of Medicine, Cape Town, South Africa

Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: ara-C
Drug: Daunorubicin
Drug: Etoposide
Biological: Aldesleukin
Drug: PSC-833

First Posted Date: 2004-07-19

Last Posted Date: 2012-11-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 410

Registration Number: NCT00002925

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States

and more 30 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2009-12-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1520

Registration Number: NCT00002549

Locations: 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 72 locations

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Biological: oblimersen sodium
Biological: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Biological: filgrastim
Biological: pegfilgrastim
Other: laboratory biomarker analysis

First Posted Date: 2004-07-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00086944

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-01

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002691

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: leucovorin calcium
Drug: liposomal cytarabine
Drug: mercaptopurine
Drug: mesna
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: thiotepa
Drug: vincristine sulfate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-01

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00002704

Locations: 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 67 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy